Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | DHODH | Q02127 | 16/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28790557 | 0.86 | PARP1 (0.54) | KDM4EPARP1HCRTR1HCRTR2 | |
| SCHEMBL5271761 | 0.86 | RIPK1 (0.60) | KDM4EPARP1HCRTR1HCRTR2 | |
| SCHEMBL1082129 | 0.85 | DHODH (0.67) | KDM4EHPGDDHODHPARP1 | |
| SCHEMBL1298127 | 0.80 | PARP1 (0.73) | KDM4EHPGDDHODHPARP1 | |
| SCHEMBL15808131 | 0.79 | KDM4E (0.56) | KDM4EHPGDDHODHPARP1 | |
| SCHEMBL4725397 | 0.78 | KDM5B (0.43) | KDM4EHPGD | |
| SCHEMBL4914829 | 0.77 | DHODH (0.50) | DHODHPARP1 | |
| SCHEMBL10687982 | 0.77 | DHODH (0.49) | KDM4EHPGDDHODHPARP1 | |
| SCHEMBL9224298 | 0.77 | KDM4E (0.54) | KDM4EHPGDDHODHPARP1 | |
| SCHEMBL4365099 | 0.76 | CBFB (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105399738-A | Azilsartan medoxomil preparation method | FANG YANYAN | 2016-03-16 | — | — | CN | claimed |
| CN-102766138-B | A kind of preparation method of Azilsartan | 温州市人民医院 | 2017-10-24 | — | — | CN | disclosed |
| CN-107056757-A | A kind of preparation method of Candesartan | 峨眉山宏昇药业股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-105399738-A | Azilsartan medoxomil preparation method | FANG YANYAN | 2016-03-16 | — | — | CN | disclosed |
| CN-105399738-A | Azilsartan medoxomil preparation method | FANG YANYAN | 2016-03-16 | — | — | CN | disclosed |
| US-8871946-B2 | Benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2014-10-28 | — | — | US | disclosed |
| EP-2386553-A1 | BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES | Shanghai Jiao Tong University (CN) | 2011-11-16 | — | — | EP | disclosed |
| US-20110269766-A1 | Benzimidazole-4-Carboxamide Derivatives, Their Preparation Methods, Pharmaceutical Compositions And Their Uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2011-11-03 | — | — | US | disclosed |
| US-20110253582-A1 | MOLDABLE ARTICLES, METHOD OF MAKING SAME AND METHOD OF MOLDING | 3M INNOVATIVE PROPERTIES COMPANY | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269766-A1 | Benzimidazole-4-Carboxamide Derivatives, Their Preparation Methods, Pharmaceutical Compositions And Their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS, HDAC6 | KDM4E 980/4885HPGD 3329/4885DHODH 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.